AZN
ASTRAZENECA'S Enhertu Wins EU CHMP Backing in Early Breast Cancer
CHMP recommended Enhertu for adjuvant use in HER2-positive early breast cancer after Phase III trial cut recurrence risk by 53%.
AZN
Market-moving news on AstraZeneca (NYSE: AZN): filings, earnings, deals and other events, from REDFILED.
AZN
ASTRAZENECA Breast Cancer Trial SERENA-4 Misses Primary Endpoint
AstraZeneca's oral SERD Etcamah plus palbociclib failed to significantly improve progression-free survival in first-line advanced ER-positive breast cancer.
AZN
FDA Approves ASTRAZENECA Breast Cancer Drug Etcamah for First-Line Use
Accelerated US approval of camizestrant with a CDK4/6 inhibitor rests on SERENA-6, which cut the risk of progression or death by 56%.